Literature DB >> 3732364

Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis.

H Albin, J M Ragnaud, F Demotes-Mainard, G Vincon, C Wone.   

Abstract

The kinetics of moxalactam has been investigated in 10 subjects undergoing continuous ambulatory peritoneal dialysis (CAPD). A single 1 g dose was injected i.v. and a 1 g dose was given intraperitoneally in the CAPD fluid during a 4 h dwell-time. Moxalactam was assayed by HPLC. After i.v. injection, the serum kinetics of moxalactam were: plasma t 1/2 = 17.9 h; volume of distribution at steady-state, 0.27 l/kg; total plasma clearance, 12.8 ml/min; peritoneal clearance, 2.1 ml/min. Dialysate moxalactam concentrations rose rapidly but only 20% of the dose was eliminated by the peritoneal route. After intraperitoneal instillation, moxalactam appeared in the serum rapidly and the peak serum concentration ranged from 21 to 49 micrograms/ml after between 4 and 5 h. The absorption of moxalactam from the peritoneal space was 57 +/- 16%. The data suggest that moxalactam has bidirectional exchange characteristics through the peritoneal membrane. Instillation of moxalactam in CAPD fluid may permit rapid absorption and the appearance of a therapeutic serum concentration.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3732364     DOI: 10.1007/bf00541532

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

Review 1.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

2.  Moxalactam kinetics during chronic ambulatory peritoneal dialysis.

Authors:  E Singlas; H F Boutron; H Merdjan; J F Brocard; M Pocheville; D Fries
Journal:  Clin Pharmacol Ther       Date:  1983-09       Impact factor: 6.875

3.  Pharmacokinetics of cefoperazone in patients undergoing chronic ambulatory peritoneal dialysis: clinical and pathophysiological implications.

Authors:  J E Hodler; R L Galeazzi; B Frey; M Rudhardt; A J Seiler
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Pharmacokinetics of intraperitoneal cefotaxime treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis.

Authors:  J Petersen; R D Stewart; G R Catto; N Edward
Journal:  Nephron       Date:  1985       Impact factor: 2.847

5.  Measurement of serum and tissue concentration of moxalactam using high pressure liquid chromatography.

Authors:  W F Diven; B D Obermeyer; R L Wolen; V L Yu; J Lyon; J Zuravleff
Journal:  Ther Drug Monit       Date:  1981       Impact factor: 3.681

6.  Moxalactam kinetics in hemodialysis.

Authors:  E J Jacobson; J J Zahrowski; A R Nissenson
Journal:  Clin Pharmacol Ther       Date:  1981-10       Impact factor: 6.875

7.  Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.

Authors:  H C Albin; F M Demotes-Mainard; J L Bouchet; G A Vincon; C Martin-Dupont
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

Review 8.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

9.  Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.

Authors:  W K Bolton; W M Scheld; D A Spyker; T L Overby; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

10.  Pharmacokinetics of moxalactam in patients with renal insufficiency.

Authors:  M Lam; C V Manion; A W Czerwinski
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

View more
  2 in total

Review 1.  Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  E Keller; P Reetze; P Schollmeyer
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.

Authors:  H Albin; J M Ragnaud; F Demotes-Mainard; G Vinçon; M Couzineau; C Wone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.